Phase II trial of idarubicin in patients with advanced lymphoma.

abstract：PURPOSE:The established treatment for small-cell lung cancer has been a cisplatin-etoposide combination, as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide but this has been unacceptable due to the toxicity. This toxicity could be attributed to the thre...

journal_title：Cancer chemotherapy and pharmacology

authors： Stathopoulos GP,Trafalis D,Dimitroulis J,Kosmas Ch,Stathopoulos J,Tsavdaridis D

更新日期：2013-02-01 00:00:00

abstract：:A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

journal_title：Cancer chemotherapy and pharmacology

authors： Looby M,Linke R,Weiss M

更新日期：1997-01-01 00:00:00

abstract：:Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-in...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Liu L,Guo Z,Liang W,He J,Huang L,Deng Q,Tang H,Pan H,Guo M,Liu Y,He Q,He J

更新日期：2017-06-01 00:00:00

abstract：PURPOSE:This study aimed to compare the survival of patients enrolled in phase 1 trials in recent decades. METHODS:The medical records of consecutive patients with advanced cancer who participated in single-agent oncology phase 1 trials from 1995 to 2015 at a single institution were retrospectively investigated. RESU...

journal_title：Cancer chemotherapy and pharmacology

authors： Ebata T,Shimizu T,Koyama T,Shimomura A,Iwasa S,Kondo S,Kitano S,Yonemori K,Fujiwara Y,Yamamoto N

更新日期：2020-02-01 00:00:00

abstract：:All-trans-retinoic acid (ATRA) has been incorporated in front-line therapy for newly diagnosed acute promyelocytic leukemia (APL). We conducted a multicenter study of differentiation therapy with ATRA alone or in combination with chemotherapy followed by intensive postremission chemotherapy in patients with APL (the J...

journal_title：Cancer chemotherapy and pharmacology

authors： Asou N,Adachi K,Tamura U,Kanamaru A,Kageyama S,Hiraoka A,Omoto E,Akiyama H,Tsubaki K,Saito K,Kuriyama K,Oh H,Kitano K,Miyawaki S,Takeyama U,Yamada O,Nishikawa K,Takahashi M,Matsuda S,Ohtake H,Ohno R

更新日期：2001-08-01 00:00:00

abstract：PURPOSE:We report on a statistical method for grouping anti-cancer drugs (GRAD) in single mouse trials (SMT). The method assigns candidate drugs into groups that inhibit or do not inhibit tumor growth in patient-derived xenografts (PDX). It determines the statistical significance of the group assignments without replic...

journal_title：Cancer chemotherapy and pharmacology

authors： Gordon D,Axelrod DE

更新日期：2019-12-01 00:00:00

abstract：PURPOSE:Eltrombopag is indicated in patients with severe aplastic anemia (SAA) refractory to prior immunosuppressive therapy. The combination of eltrombopag and immunosuppressive therapy (such as cyclosporine) is currently being evaluated in patients with treatment-naive SAA. Cyclosporine is a human breast cancer resis...

journal_title：Cancer chemotherapy and pharmacology

authors： Aslanis V,Zhang J,Lomeli B,Grosch K,Ouatas T

更新日期：2018-11-01 00:00:00

abstract：:Eighteen previously untreated patients with advanced unresectable or metastatic soft-tissue sarcomas (STS) and two patients with locally invasive thymoma were treated with a combination of adriamycin (ADM) 80 mg/m2 on day 1 and cis-platinum (DDP) 120 mg/m2 on day 1. The regimen was repeated at 4-weeks intervals. In ST...

journal_title：Cancer chemotherapy and pharmacology

authors： Klippstein TH,Mitrou PS,Kochendörfer KJ,Bergmann L

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:Based on the results of first-line chemotherapy for advanced pancreatic cancer, S-1 was confirmed to be non-inferior to gemcitabine. However, the recommended regimen of 4 weeks of administration followed by 2 weeks of drug withdrawal frequently causes adverse effects. On the other hand, we experienced in clinic...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamaue H,Satoi S,Kanbe T,Miyazawa M,Tani M,Kawai M,Hirono S,Okada K,Yanagimoto H,Kwon AH,Mukouyama T,Tsunoda H,Chijiiwa K,Ohuchida J,Kato J,Ueda K,Yamaguchi T,Egawa S,Hayashi K,Shirasaka T

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Head and neck squamous carcinoma (HNSCC) is a chemotherapy-sensitive tumour, but this sensitivity is not reflected in an impact on survival. The study of new drugs is therefore indicated. Pirarubicin (4'-O-tetrahydropyranyl-doxorubicin) has a higher preclinical index than doxorubicin, with low cardiotoxicity...

journal_title：Cancer chemotherapy and pharmacology

authors： De Mulder PH,Cappelaere P,Cognetti F,Verweij J,Schornagel JH,Vermorken JB,Kirkpatrick A,Lefebvre JL

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. PATIENTS AND METHODS:A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) o...

journal_title：Cancer chemotherapy and pharmacology

authors： Feliu J,Firvida JL,Castro J,Madroñal C,Rodríguez-Jaráiz A,Salgado M,Belda-Iniesta C,Casado E,García-Mata J,González-Barón M,Oncopaz Cooperative Group.

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:In this phase II clinical trial, we evaluated the efficacy and safety of S-1 monotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We also measured plasma concentrations of 5-fluorouracil (5-FU) and 5-chloro-2,4-dihydroxypyridine components of S-1 and examined correlati...

journal_title：Cancer chemotherapy and pharmacology

authors： Wada M,Yamamoto M,Ryuge S,Nagashima Y,Hayashi N,Maki S,Otani S,Katono K,Takakura A,Yanaihara T,Igawa S,Yokoba M,Mitsufuji H,Kubota M,Katagiri M,Masuda N

更新日期：2012-04-01 00:00:00

abstract：:Experimental evidence indicates that the anthracycline antibiotic doxorubicin (adriamycin) localizes mainly in cell nuclei of cardiac cells and has a high affinity to several cellular constituents in addition to DNA. In the present study the cellular kinetics of doxorubicin in cultured rat myocardial cells were determ...

journal_title：Cancer chemotherapy and pharmacology

authors： Wassermann K,Steiness E

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:P-glycoprotein is a 170-kDa plasma membrane multidrug transporter that actively exports cytotoxic substances from cells. Overexpression of P-glycoprotein by tumor cells is associated with a multidrug-resistant phenotype. Immunosuppressive agents such as cyclosporins and macrolides, have been shown to attenuate ...

journal_title：Cancer chemotherapy and pharmacology

authors： Mealey KL,Barhoumi R,Burghardt RC,McIntyre BS,Sylvester PW,Hosick HL,Kochevar DT

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:This study compared the pharmacokinetics of PF-06439535, a potential bevacizumab biosimilar, to bevacizumab sourced from the European Union (bevacizumab-EU) and USA (bevacizumab-US), and of bevacizumab-EU to bevacizumab-US. METHODS:In this double-blind study, 102 healthy males, aged 21-55 years, were randomize...

journal_title：Cancer chemotherapy and pharmacology

authors： Knight B,Rassam D,Liao S,Ewesuedo R

更新日期：2016-04-01 00:00:00

abstract：:We obtained evidence that the cytotoxic effect of 5-fluorouracil (5-FU) is augmented when the drug is given in combination with hyperthermia (HYP) and dipyridamole (DP). Nontoxic levels of DP enhanced the combined cytotoxicity of 5-FU and HYP against B16 melanoma and human tumor cells in vitro as measured by the succi...

journal_title：Cancer chemotherapy and pharmacology

authors： Maehara Y,Sakaguchi Y,Takahashi I,Yoshida M,Kusumoto H,Masuda H,Sugimachi K

更新日期：1992-01-01 00:00:00

abstract：:A combination of carboplatin, vincristine, methotrexate and bleomycin (COMB) was given to 29 patients with locally advanced, metastatic or recurrent cervical carcinoma. A total of 85 cycles of chemotherapy were given, with half of the patients receiving greater than 3 cycles. Both the response rate (32.1%) and the med...

journal_title：Cancer chemotherapy and pharmacology

authors： Junor E,Davies J,Habeshaw T,Kaye S,Paul J,Rankin E,Reed N,Symonds RP

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:Streptozocin (STZ) is a key agent for treating advanced pancreatic neuroendocrine tumors (pNET). Most STZ regimens for pNET are daily and also include 5-fluorouracil (5FU), whereas STZ monotherapy and weekly regimens have also been applied in daily practice in Japan. The present study aimed to evaluate response...

journal_title：Cancer chemotherapy and pharmacology

authors： Shibuya H,Hijioka S,Sakamoto Y,Ito T,Ueda K,Komoto I,Kobayashi N,Kudo A,Yasuda H,Miyake H,Arita J,Kiritani S,Ikeda M,Imaoka H,Ueno M,Kobayashi S,Furuta M,Nagashio Y,Murohisa G,Aoki T,Matsumoto S,Motoya M,Azemo

更新日期：2018-10-01 00:00:00

abstract：:Some of 66 patients with head and neck tumors were treated with high-dose methotrexate monochemotherapy. The use of a prospective mathematical model with pharmacokinetic surveillance proved to be reliable, practical, and useful. By this means chemotherapy could be individualized, with a resultant marked reduction in t...

journal_title：Cancer chemotherapy and pharmacology

authors： Favre R,Monjanel S,Alfonsi M,Pradoura JP,Bagarry-Liegey D,Clement S,Imbert AM,Lena N,Colonna d'Istria J,Cano JP,Carcassonne Y

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA. METHODS:In vitro chemical inhibition studies were conducted by incubating thiotepa and pooled human hepatic microsomes in the presence of known inhibit...

journal_title：Cancer chemotherapy and pharmacology

authors： Jacobson PA,Green K,Birnbaum A,Remmel RP

更新日期：2002-06-01 00:00:00

abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

journal_title：Cancer chemotherapy and pharmacology

authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

更新日期：2017-12-01 00:00:00

abstract：PURPOSE:Mutations and activations of the MEK and PI3K pathways are associated with the development of many cancers. GDC-0973 and GDC-0941 are inhibitors of MEK and PI3K, respectively, currently being evaluated clinically in combination as anti-cancer treatment. The objective of these studies was to characterize the rel...

journal_title：Cancer chemotherapy and pharmacology

authors： Choo EF,Ng CM,Berry L,Belvin M,Lewin-Koh N,Merchant M,Salphati L

更新日期：2013-01-01 00:00:00

abstract：:Dihydroartemisinin (DHA), a more water-soluble active metabolite of artemisinin derivatives, is safe and the most effective antimalarial analog of artemisinin. In the present investigation, we assessed the effect of DHA on vascular endothelial growth factor (VEGF) expression and apoptosis in chronic myeloid leukemia (...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee J,Zhou HJ,Wu XH

更新日期：2006-01-01 00:00:00

abstract：PURPOSE:There is as yet no optimal treatment regimen for patients with epidermal growth factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has progressed despite cytotoxic chemotherapy. This trial was performed to evaluate the efficacy and toxicity of erlotinib, a tyrosine kinase inhibitor of...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi T,Koizumi T,Agatsuma T,Yasuo M,Tsushima K,Kubo K,Eda S,Kuraishi H,Koyama S,Hachiya T,Ohura N

更新日期：2012-05-01 00:00:00

abstract：PURPOSE:The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced m...

journal_title：Cancer chemotherapy and pharmacology

authors： Spieth K,Kaufmann R,Gille J

更新日期：2003-11-01 00:00:00

abstract：PURPOSE:This study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble poly(ethylene) glycol conjugate of SN38. METHODS:Patients with advanced malignancies were enrolled in dose-escalating cohorts (3 + 3 design). EZN-2208 was administered as a 1-h intravenous i...

journal_title：Cancer chemotherapy and pharmacology

authors： Patnaik A,Papadopoulos KP,Tolcher AW,Beeram M,Urien S,Schaaf LJ,Tahiri S,Bekaii-Saab T,Lokiec FM,Rezaï K,Buchbinder A

更新日期：2013-06-01 00:00:00

abstract：PURPOSE:6-Gingerol, a major biochemical and pharmacological active ingredient of ginger, has shown anti-inflammatory and antitumor activities against various cancers. Searching for natural products with fewer side effects for developing adjunctive therapeutic options is necessary. METHODS:The effects of 6-gingerol on ...

journal_title：Cancer chemotherapy and pharmacology

authors： Xu S,Zhang H,Liu T,Yang W,Lv W,He D,Guo P,Li L

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Therapeutic approach for patients with metastatic breast cancer (MBC) is still controversial. This study was conducted to assess the efficacy and safety of bevacizumab in combination with docetaxel plus capecitabine as first-line treatment for MBC. The feasibility of bevacizumab maintenance therapy in this s...

journal_title：Cancer chemotherapy and pharmacology

authors： Bisagni G,Musolino A,Panebianco M,De Matteis A,Nuzzo F,Ardizzoni A,Gori S,Gamucci T,Passalacqua R,Gnoni R,Moretti G,Boni C

更新日期：2013-04-01 00:00:00

abstract：:We compared concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF) with CCRT with CDDP, 5-FU, methotrexate and leucovorin (PFML) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in terms of safety and efficacy on survival. A total of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsukuda M,Ishitoya J,Matsuda H,Horiuchi C,Taguchi T,Takahashi M,Nishimura G,Kawakami M,Watanabe M,Niho T,Kawano T,Ikeda Y,Sakuma Y,Shiono O,Komatsu M

更新日期：2010-09-01 00:00:00

abstract：PURPOSE:Artemisinins are now established drugs for treatment of malaria. These agents have been shown to possess impressive anti-cancer properties. We have investigated the role of artemisone (ATM), a novel derivative of artemisinin (ART) in a cancer setting both alone and in combination with established chemotherapeut...

journal_title：Cancer chemotherapy and pharmacology

authors： Gravett AM,Liu WM,Krishna S,Chan WC,Haynes RK,Wilson NL,Dalgleish AG

更新日期：2011-03-01 00:00:00